profit from every $100 of sales.
$0$100
Immuron
$0.93+3.04% today
-42.8% in 1 year
1-year low $0.701-year high $1.84
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Immuron sold, what it kept, and what it did with the cash.
Sales went from A$765,193 in 2022 to A$7.29 million in 2025, with -A$5.22 million of profit last year.
SalesProfit
Immuron vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Immuron | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Immuron's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 2 | 5 | 7 | |
| 1 | 1 | 3 | 5 | |
| -3 | -3 | -5 | -5 | |
| -3 | -4 | -7 | -5 | |
| -3 | -4 | -7 | -5 | |
| -0.50 | -0.66 | -1.22 | -0.91 | |
| 68.4% | 72.5% | 68.1% | 65.4% | |
| -407.4% | -188.8% | -106.4% | -73.5% | |
| -373.0% | -209.8% | -141.5% | -71.6% |
Balance sheet
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 25 | 22 | 16 | 10 |
| Cash | 22 | 17 | 12 | 3 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 2 | 2 | 3 | 2 |
| 23 | 20 | 13 | 8 | |
| 6 | 6 | 6 | 6 | |
| -9.6% | -15.1% | -42.6% | -50.5% | |
| -12.3% | -19.3% | -54.6% | -64.6% |
Cash flow
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| 0 | 0 | 0 | – | |
| -3 | -3 | -6 | -6 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- 0.6×
- 1.5×
- –
- –
- -56.2%
- -47.7%
- 0.0%
Profitability
- 65.4%
- -73.5%
- -71.6%
- -67.9%
- -29.0%
- -36.3%
- -43.9%
- -30.7%
- -38.5%
- 37.4%
Growth
- +112.0%
- –
- −4.4%
- –
- +1.1%
Financial health
- -0.5×
- 0.00
- 0.0%
- -518.1×
- 8.04
- 6.83
- 0.49
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 958
Bottom 5%of 888
Top 5%of 889
Bottom 1%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 25, 2026 | -0.20 | -0.01 | −2,586.2% |
| Aug 28, 2025 | -0.31 | -0.01 | −2,219.5% |
| Mar 31, 2025 | -0.14 | – | – |
| Feb 28, 2025 | -0.27 | -0.01 | −1,922.7% |
| Sep 30, 2024 | -0.15 | – | – |
| Aug 29, 2024 | -0.57 | – | – |
| Apr 29, 2024 | -0.25 | – | – |
| Mar 31, 2024 | -0.28 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
72Pass
Philip Fisher
51No pass
Peter Lynch
50No pass
Joel Greenblatt
0No pass
Charlie Munger
43No pass
Terry Smith
46No pass
Questions about Immuron
Is Immuron a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Immuron AI analysis
What does Immuron do?
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It is in Biotechnology.
Does Immuron pay a dividend?
No. Immuron does not pay a dividend at the moment.
Is Immuron stock halal?
Yes. Immuron passes our halal screen: its business is permitted and its debt is 0.7% of its market value, under the 30% limit. How we check
How has Immuron stock done over the past year?
Down 42.8% over the past twelve months, to $0.93. It traded between $0.70 and $1.84 and is 49.6% below its high.
Who are Immuron's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Immuron's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.